NASDAQ · BPTS
Healthcare · Biotechnology
$8.22
Down-$1.28 (-13.47%)
Updated Aug 25, 2026, 12:07 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
BPTS does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning BPTS.
BPTS research
Company profile and research snapshot.
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 16, 2023 | HC Wainwright & Co. | Buy | — |
| Aug 8, 2023 | HC Wainwright & Co. | Buy | — |
| Feb 27, 2023 | HC Wainwright & Co. | Buy | — |
| Feb 3, 2023 | HC Wainwright & Co. | Buy | — |
| Oct 25, 2021 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Zacks Investment Research · Apr 9, 2024
Biophytis (BPTS) rises in the after-market hours as it announces the launch of a new clinical development program for its investigational candidate, BIO101, to treat obesity in combination with GLP-1 drugs.
Benzinga · Nov 24, 2023
U.S. stocks traded mixed this morning, with the Dow Jones index gaining around 50 points on Friday. Following the market opening Friday, the Dow traded up 0.14% to 35,323.77 while the NASDAQ fell 0.13% to 14,247.68. The S&P 500 also fell, dropping, 0.02% to 4,555.53. Check This Out: Visa, KeyCorp And 2 Other Stocks Insiders Are Selling Leading and Lagging Sectors Energy shares surged by 0.6% on Friday. In trading on Friday, real estate shares fell by 0.5%. Top Headline Amazon.com Inc.’s (NASDAQ: AMZN) proposed acquisition of iRobot Corp. (NASDAQ: IRBT), the popular Roomba robot vacuum manufacturer, is reportedly on the verge of receiving unconditional approval from European Union antitrust authorities. Equities Trading UP FLJ Group Limited (NASDAQ: FLJ) shares shot up 137% to $0.2564 after the company announced it entered into a definitive agreement to acquire Alpha Mind Technology. Shares of BioNexus Gene Lab Corp. (NASDAQ: BGLC) got ...
Zacks Investment Research · Sep 26, 2023
Biophytis (BPTS) gains on signing a partnership with Skyepharma, for the production of regulatory batches of its lead candidate, Sarconeos (BIO101).
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BPTS.
No results
No recent SID articles mention BPTS.
